Sort
30,917 grants matching “tumor microenvironment”
Immune biological differences between Triple Negative Breast Cancer in African American and non-African American women and potential immunotherapy opportunities to improve treatment outcome
$419,283Lajos Pusztai · Yale University · R01 · FY2018 · CA
Determination of functional and molecular biomarkers of treatment resistance with multimodal optical spectroscopy
$419,281Narasimhan Rajaram · University Of Arkansas At Fayetteville · R01 · FY2020 · CA
Characterization of the interaction between inflammation and cancer progression
$419,278Robert Wiltrout · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Mechanisms of Leukocyte Migration Following Cytokine Administration to Mice
$419,278Robert Wiltrout · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Mouse models of glioma to study functional exRNA transfer to the microenvironmen
$419,247Xandra Owens Breakefield · Massachusetts General Hospital · U19 · FY2017 · CA
Role of IKK alpha in lymphoid organ development
$419,198Yinling Hu · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Induction of Tumor Immunity by Secreted HSP-gp96
$419,167Eckhard R Podack · University Of Miami School Of Medicine · P01 · FY2007 · CA
EGFRvIII-targeted Bispecific T cell Engagers for brain tumors
$419,152John H Sampson · Duke University · R01 · FY2014 · NS
Leveraging combination histotripsy tumor ablation and N-dihydrogalactochitosan immunostimulation to advance osteosarcoma therapy
$419,080Joanne Tuohy · Virginia Polytechnic Inst And St Univ · R21 · FY2025 · CA
Targeting TREM2 to boost anti-cancer therapy
$419,032Marco Colonna · Washington University · R01 · FY2024 · CA
Fatty Acid Synthase: Characterization as a Novel Molecular Target for Breast Can*
$418,986Ruth Lupu · Northshore University Healthsystem · R01 · FY2006 · CA
Targeting tumor repopulation and the immune microenvironment to overcome chemoresistance
$418,910Keith Syson Chan · Methodist Hospital Research Institute · R01 · FY2023 · CA
Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy & Chemoprevention
$418,872Ruth Lupu · Northshore University Healthsystem · R01 · FY2007 · CA
Synstatin Therapy for Multiple Myeloma
$418,831Alan C Rapraeger · University Of Wisconsin-Madison · R01 · FY2010 · CA
Three-dimensional organoid models to study breast cancer progression
$418,813Shilpa Sant · University Of Pittsburgh At Pittsburgh · R37 · FY2022 · CA
How does EGFR facilitate the constitutive activation of STAT3 in tumors?
$418,801George Robert Stark · Cleveland Clinic Lerner Com-Cwru · P01 · FY2019 · CA
Elucidating genetics of response to immune checkpoint blockade in lung cancer
$418,751Timothy An-Thy Chan · Cleveland Clinic Lerner Com-Cwru · R01 · FY2021 · CA
Toward understanding the role of altered glycosylation in cancer
$418,750Stacy Alyse Malaker · Yale University · R35 · FY2023 · GM
Toward understanding the role of altered glycosylation in cancer
$418,750Stacy Alyse Malaker · Yale University · R35 · FY2025 · GM
Toward understanding the role of altered glycosylation in cancer
$418,750Stacy Alyse Malaker · Yale University · R35 · FY2024 · GM
A Chemical Strategy of Developing Resistance-Proof, Immune-Friendly Drugs
$418,748Probal Banerjee · College Of Staten Island · R15 · FY2021 · CA
Systematic characterization of cancer variants using single-cell functional genomics
$418,693Thomas Maxwell Norman · Sloan-Kettering Inst Can Research · R33 · FY2024 · CA
Targeting immune suppressive microenvironment in ATC
$418,682James A Fagin · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
Supplement to PO1 CA-80124-03-Integrative Pathophysiol
$418,679Massachusetts General Hospital · P01 · FY2003 · CA
Expression of recombinant Fc receptors by engineered NK cells to enhance cancer cell killing
$418,599Bruce K Walcheck · University Of Minnesota · R01 · FY2024 · CA